Predictive value of cerebrospinal fluid matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 concentrations in childhood bacterial meningitis

Pediatric Infectious Disease Journal

Volumn 33, Issue 7, 2014, Pages 675-679

  Roine, Irmeli ^a   Pelkonen, Tuula ^b,c   Bernardino, Luis ^b   Lauhio, Anneli ^d   Tervahartiala, Taina ^e   Lappalainen, Maija ^f   Kataja, Matti ^g   Pitkäranta, Anne ^g   Sorsa, Timo ^e,h   Peltola, Heikki ^c  

^a UNIVERSIDAD DIEGO PORTALES   (Chile)

^b David Bernardino Children's Hospital   (Angola)

^c Children's Hospital   (United States)

^d Division of Infectious Diseases   (United States)

^e Department of Oral and Maxillofacial Diseases ^*  (United States)

^f Department of Virology and Immunology Laboratory Services (HUSLAB) Helsinki University Central Hospital   (Colombia)

^g HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^h UNIVERSITY OF HELSINKI   (Finland)

Author keywords

bacterial meningitis; childhood; matrix metalloproteinase 9; outcome; tissue inhibitor of metalloproteinase

Indexed keywords

GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 1; BIOLOGICAL MARKER; MMP9 PROTEIN, HUMAN; TIMP1 PROTEIN, HUMAN;

ARTICLE; BACTERIAL MENINGITIS; CEREBROSPINAL FLUID LEVEL; CHILD; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GLASGOW COMA SCALE; HUMAN; MAJOR CLINICAL STUDY; NONHUMAN; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; CEREBROSPINAL FLUID; EVALUATION STUDY; MENINGITIS, BACTERIAL; PATHOLOGY; PRESCHOOL CHILD;

BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MATRIX METALLOPROTEINASE 9; MENINGITIS, BACTERIAL; PREDICTIVE VALUE OF TESTS; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 84902536769     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000000249     Document Type: Article

References (22)

1. Edmond K, Clark A, Korczak VS, et al. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10:317-328.
2. Peltola H. Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. Clin Microbiol Rev. 2000;13:302-317.
3. McIntyre PB, O'Brien KL, Greenwood B, et al. Effect of vaccines on bacterial meningitis worldwide. Lancet. 2012;380:1703-1711.
4. Roine I, Peltola H, Fernández J, et al. Influence of admission findings on death and neurological outcome from childhood bacterial meningitis. Clin Infect Dis. 2008;46:1248-1252.
5. Mustafa MM, Lebel MH, Ramilo O, et al. Correlation of interleukin-1 beta and cachectin concentrations in cerebrospinal fluid and outcome from bacterial meningitis. J Pediatr. 1989;115:208-213.
6. Leppert D, Leib SL, Grygar C, et al. Matrix metalloproteinase (MMP)-8 and MMP-9 in cerebrospinal fluid during bacterial meningitis: association with blood-brain barrier damage and neurological sequelae. Clin Infect Dis. 2000;31:80-84.
7. Lindberg RL, Sorsa T, Tervahartiala T, et al. Gelatinase B [matrix metalloproteinase (MMP)-9] and collagenases (MMP-8/-13) are upregulated in cerebrospinal fluid during aseptic and bacterial meningitis in children. Neuropathol Appl Neurobiol. 2006;32:304-317.
8. Tsai HC, Shi MH, Lee SS, et al. Expression of matrix metalloproteinases and their tissue inhibitors in the serum and cerebrospinal fluid of patients with meningitis. Clin Microbiol Infect. 2011;17:780-784.
9. Paul R, Lorenzl S, Koedel U, et al. Matrix metalloproteinases contribute to the blood-brain barrier disruption during bacterial meningitis. Ann Neurol. 1998;44:592-600.
10. Yushchenko M, Weber F, Mäder M, et al. Matrix metalloproteinase-9 (MMP-9) in human cerebrospinal fluid (CSF): elevated levels are primarily related to CSF cell count. J Neuroimmunol. 2000;110:244-251.
11. Tsai HC, Liu SF, Wu KS, et al. Dynamic changes of matrix metalloproteinase- 9 in patients with Klebsiella pneumoniae meningitis. Inflammation. 2008;31:247-253.
12. Vanlaere I, Libert C. Matrix metalloproteinases as drug targets in infections caused by Gram-negative bacteria and in septic shock. Clin Microbiol Rev. 2009;22:224-39, Table of Contents.
13. Leib SL, Clements JM, Lindberg RL, et al. Inhibition of matrix metalloproteinases and tumour necrosis factor alpha converting enzyme as adjuvant therapy in pneumococcal meningitis. Brain. 2001;124(pt 9):1734-1742.
14. Meli DN, Christen S, Leib SL. Matrix metalloproteinase-9 in pneumococcal meningitis: activation via an oxidative pathway. J Infect Dis. 2003;187:1411-1415.
15. McIntyre PB, Berkey CS, King SM, et al. Dexamethasone as adjunctive therapy in bacterial meningitis. A meta-analysis of randomized clinical trials since 1988. JAMA. 1997;278:925-931.
16. Mustafa MM, Ramilo O, Mertsola J, et al. Modulation of inflammation and cachectin activity in relation to treatment of experimental Hemophilus influenzae type b meningitis. J Infect Dis. 1989;160:818-825.
17. Pelkonen T, Roine I, Cruzeiro ML, et al. Slow initial ?-lactam infusion and oral paracetamol to treat childhood bacterial meningitis: a randomised, controlled trial. Lancet Infect Dis. 2011;11:613-621.
18. Lauhio A, Hästbacka J, Pettilä V, et al. Serum MMP-8, -9 and TIMP-1 in sepsis: high serum levels of MMP-8 and TIMP-1 are associated with fatal outcome in a multicentre, prospective cohort study. Hypothetical impact of tetracyclines. Pharmacol Res. 2011;64:590-594.
19. Pelkonen T, Roine I, Monteiro L, et al. Prognostic accuracy of five simple scales in childhood bacterial meningitis. Scand J Infect Dis. 2012;44:557-565.
20. Sorsa T, Tjäderhane L, Konttinen YT, et al. Matrix metalloproteinases: contribution to pathogenesis, diagnosis and treatment of periodontal inflammation. Ann Med. 2006;38:306-321.
21. Herr AE, Hatch AV, Throckmorton DJ, et al. Microfluidic immunoassays as rapid saliva-based clinical diagnostics. Proc Natl Acad Sci USA. 2007;104:5268-5273.
22. Sorsa T, Tervahartiala T, Leppilahti J, et al. Collagenase-2 (MMP-8) as a point-of-care biomarker in periodontitis and cardiovascular diseases. Therapeutic response to non-antimicrobial properties of tetracyclines. Pharmacol Res. 2011;63:108-113.